Clinical Trial Update: Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating tucidinostat plus exemestane in early breast cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• Tucidinostat (tucidinostat)

Snippet

Sponsor: First Affiliated Hospital, Sun Yat-Sen University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED